Abstract
Aim:
To investigate whether the CYP3A5*3 polymorphism would affect cyclosporine A (CsA) metabolism in Chinese renal transplant patients.
Methods:
The CYP3A5*3 genotype was determined in Chinese renal transplant recipients using polymerase chain reaction and amplification of specific alleles (PCR-ASA). The concentrations of CsA and metabolites were separately measured by fluorescence polarization immunoassay and dose-adjusted trough concentrations and metabolic ratio (MR) values were calculated.
Results:
The trough concentrations adjusted with the dose was significantly higher in the wild allele carriers compared to both the homozygous (*3*3) and heterozygous variants (*1 *3). However, no significant difference was found for the dose-adjusted metabolite concentrations. The MR values for the 3 genotype groups were as follows: 0.92±0.62 for CYP3A5*3/ *3 (n=14), 0.99±0.51 for CYP3A5*1/*3 (n=15), and 1.45±0.62 for CYP3A5*1/*1 (n=9), respectively. Post hoc comparisons showed that only the MR values between the CYP3A5*3/*3 group and the CYP3A5*1/*1 group were significantly different.
Conclusion:
The CYP3A5*3 polymorphism exerted little effect on cyclosporine metabolism. The MR may be a more accurate indicator for therapeutic drug monitoring, considering its integrated information on body exposure of both parent drugs and metabolites.
Similar content being viewed by others
Article PDF
References
Guengerich FP . Reactions and significance of cytochrome P-450 enzymes. J Biol Chem 1991; 266: 10019–22.
Evans WE, Mcleod HL . Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538–49.
Shih PS, Huang JD . Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 2002; 30: 1491–6.
Hustert E, Haber M, Burk O, Wolbold R, He YQ, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Phar-macogenetics 2001; 11: 773–9.
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization if the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383–91.
Min DI, Ku YM, Vichiendilokkul A, Fleckenstein LL . A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers. Pharmacotherapy 1999; 19: 753–9.
Hesselink DA, van-Schaik RH, van-der-Heiden IP, van-der-Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245–54.
Anglicheau D, Thervet E, Etienne I, Hurault DLB, Le MY, Touchard G, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin pharmacol Ther 2004; 75: 422–33.
Hesselink DA, van-Gelder T, van-Schaik RH, Balk AH, van-der-Heiden IP, van Dam T, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphism in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76: 545–56.
Haufroid V, Mourad M, Van KV, Wawrzyniak J, De Meyer M, Eddour DC, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphism on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Phar-macogenetics 2004; 14: 147–54.
Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM . Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998; 66: 59–66.
Wallemacq PE, Alexandre K . Evaluation of the new AxSYM cyclosporine assay: comparison with TDx monoclonal whole blood and emit cyclosporine assays. Clin Chem 1999; 45: 432–35.
Williams JA, Cook J, Susan I, Hurst SI . A significant drug-metabolizing role for CYP3A5?. Drug Metab Dispos 2003; 31: 1526–30.
Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003; 43: 555–64.
Aros CA, Ardiles LG, Schneider HO, Flores CA, Alruiz PA, Jerez VR, et al. No gender-associated differences of cyclosporine pharmacokinetics in stable renal transplant patients treated with diltiazem. Transplant Proc 2005; 37: 3364–6.
Christians U, Sewing KF . Alternative cyclosporine metabolic pathways and toxicity. Clin Biochem 1995; 28: 547–59.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chu, Xm., Hao, Hp., Wang, Gj. et al. Influence of CYP3A5 genetic polymorphism on cyclosporine A metabolism and elimination in Chinese renal transplant recipients. Acta Pharmacol Sin 27, 1504–1508 (2006). https://doi.org/10.1111/j.1745-7254.2006.00428.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2006.00428.x
Keywords
This article is cited by
-
Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients
Acta Pharmacologica Sinica (2013)
-
Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China
Acta Pharmacologica Sinica (2012)
-
The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis
The Pharmacogenomics Journal (2011)
-
CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine
The Pharmacogenomics Journal (2008)
-
Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients
European Journal of Clinical Pharmacology (2008)